March 20, 2025 06:31 AM EDT
Deals

Sanofi to pay $600M up­front for Dren Bio’s bis­pe­cif­ic B cell de­pleter

Elizabeth Cairns

Senior biopharma journalist

Sanofi is buy­ing a B cell-de­plet­ing an­ti­body de­vel­oped by Dren Bio as a ther­a­py for can­cer and au­toim­mune dis­eases.

The phar­ma said

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

TRENDING NOW

No­vo Nordisk says new ear­ly R&D struc­ture will ‘fu­ture-proof’ its busi­ness

Up­dat­ed: FDA ap­proves Al­ny­lam’s Amvut­tra in AT­TR-CM, kick­ing off com­pe­ti­tion with Pfiz­er, Bridge­Bio

Akero ex­ec calls FDA's ac­cel­er­at­ed ap­proval guid­ance for MASH drugs 'bizarre'

CDC vac­cine meet­ing, de­layed ear­li­er this year, is resched­uled

Two-thirds of re­cent rare dis­ease drugs re­lied on just one tri­al, plus con­fir­ma­to­ry ev­i­dence, FDA team finds

Cal­ley Means joins White House as a spe­cial gov­ern­ment em­ploy­ee, will as­sist with MA­HA poli­cies

A service from the Financial Times